Clinical Trial Update: Evaluation of Optimal Treatment Duration of Bevacizumab Combination With Standard Chemotherapy in Patients With Ovarian Cancer [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the optimal duration of bevacizumab in combination with standard chemotherapy for ovarian cancer has completed enrollment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: AGO Study Group | Conditions: Genital Diseases, Female, Ovarian Diseases | Phase 3 | Status: COMPLETED